View More Recent Stories
-
Bausch Health Companies (BHC) PT Lowered to $8.50 at RBC Capital
-
Piper Sandler Downgrades Bausch Health Companies (BHC) to Underweight
-
Bausch Health Announces Second Quarter 2024 Results
-
Jefferies on Bausch Health Companies (BHC): 'Another Case of Irresponsible Journalism Wreaks Havoc in Shares'
-
Bausch Health (BHC) denies reports, not involved in bankruptcy discussions
-
Bausch Health Responds to Market Rumors
-
Truist on Bausch Health Companies (BHC) Bankruptcy Rumors: 'we think a potential bankruptcy filing would place the separation on hold'
-
Bausch Health (BHC) halted, news pending, company is rumored to be negotiating chapter 11 bankruptcy filing
-
Bausch Health Co. Inc. (BHC) Halted on Volatility, Down 31%
-
Bausch Health Welcomes Two New Members to the Executive Leadership Team
-
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
-
Bausch Health (BHC) Files Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
-
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
